Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanying Li

Showing results (201-210 of 203) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 203 results.
European Journal of Heart Failure|June 20, 2020
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trialAdriaan A Voors, Jean-François Tamby, John G Cleland, et al.
Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2024
Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 TrialRuinuo Jia, Tanyou Shan, Anping Zheng, et al.
Pageof 21

Showing results (201-210 of 203) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 203 results.
European Journal of Heart Failure|June 20, 2020
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trialAdriaan A Voors, Jean-François Tamby, John G Cleland, et al.
Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2024
Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 TrialRuinuo Jia, Tanyou Shan, Anping Zheng, et al.
Pageof 21